Brind.
  1. A collection of industry news reported on June 6th, including Akeso's success reported by China Daily, the general trend of Chinese companies outpacing Western counterparts, and the ASCO meeting held in Chicago.

Akeso, a Zhongshan-based company in Guangdong, reported that its drug outperformed MSD's Keytruda in trials, showcasing the rise of Chinese biotech.

5 reports, 2 independent Updated Sep 4
Gone quiet Reached 4 outlets in its first 24 hours
Reports
5
Developments
2
Repetition
60%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Akeso, a Zhongshan-based company in Guangdong, reported that its drug outperformed MSD's Keytruda in trials, showcasing the rise of Chinese biotech.

Who's involved

What this event is mainly about
AkesoDeepSeekMSD

How it developed

Newest first. Tap a step to see who reported it.
  1. Akeso's drug outperformed Keytruda; Yu Xia appointed CEO.1 source
  2. Akeso drug outperformed MSD's Keytruda in trials, highlighting the rise of biotech in Guangdong.1 source

Keep exploring

Part of

A collection of industry news reported on June 6th, including Akeso's success reported by China Daily, the general trend of Chinese companies outpacing Western counterparts, and the ASCO meeting held in Chicago. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
3 more outlets ran the same wire story